STAT

Amgen’s new migraine drug will cost 30 percent less than Wall Street expected

Source: Mark J. Terrill/AP

Amgen will charge $6,900 a year for a new drug that can spare migraine sufferers a few headaches each month, a price that comes in well below Wall Street expectations as the company hopes to avoid the payer backlash that has hamstrung recent drug launches.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readPolitics
These Republicans Campaigned On A Bold Drug-pricing Pledge. Since They Won, They’ve Gone Silent
These Republicans campaigned in 2018 on a pledge to allow Medicare to negotiate for drug prices. Since they won, they’ve gone silent.
STAT2 min read
California Names Former Google Scientist As The State’s ‘Mental Health Czar’
Dr. Tom Insel, a prominent neuroscientist who once led the National Institute of Mental Health, is going to be the “mental health czar” for the state of California.
STAT4 min readSociety
Opinion: Prejudice And Patient Choice: An Insidious Confluence In Medicine
Minority physicians like me often hear patients say things like, "I don't want your kind taking care of me!" That kind of racism has no place in health care.